Immuneering Appoints Andrew Gengos as Chief Financial Officer
Immuneering appointed Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Gengos joins from Terns Pharmaceuticals, which was acquired by Merck for $6.7 billion, bringing over 25 years of biotech leadership experience.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.